Stay updated on Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.

Latest updates to the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.3%
- Check21 days agoChange DetectedThe web page has been updated to a new version, v2.16.11, with the previous version, v2.16.10, being removed. The date has also changed from July 20, 2025, to August 7, 2025.SummaryDifference0.6%
- Check28 days agoChange DetectedThe page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference4%
- Check35 days agoChange DetectedThe page has been updated to reflect a new revision version (v2.16.8) and a new date (2025-07-20), replacing the previous revision (v2.16.6) and date (2025-06-19).SummaryDifference1%
- Check43 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.3%
- Check50 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference4%
Stay in the know with updates to Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib & Trastuzumab in HER2+ Solid Tumors Clinical Trial page.